[Precocious puberty associated with Von Recklinghausen's disease. Developmental follow-up under cyproterone acetate treatment].
Authors describe a case of a boy aged 8-10/12 years with precocious puberty associated with Von Recklinghausen's disease. He was treated with cyproterone acetate (100 mg/m2/24 h oral doses) and controlled for a period of two years. He shows very few effects of puberal physical signs and improvement of his sexual behavioral area. They have evaluated growth evolution by different parameters and couldn't appreciate any improvement because of the advanced bone age (13-6/12 years) when treatment was started.
D000328:Adult; D000365:Age Determination by Skeleton; D001827:Body Height; D002648:Child; D002653:Child Behavior Disorders / Q000209:etiology; D003534:Cyproterone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017373:Cyproterone Acetate; D005260:Female; D006801:Humans; D007029:Hypothalamic Neoplasms / Q000150:complications; D008297:Male; D009456:Neurofibromatosis 1 / Q000150:complications*; D011629:Puberty, Precocious / Q000150:complications* / Q000188:drug therapy / Q000523:psychology; D012878:Skin Neoplasms / Q000150:complications*
D017373:Cyproterone Acetate; D003534:Cyproterone
Pubertad precoz asociada a enfermedad de Von Recklinghausen. Seguimiento evolutivo bajo tratamiento con acetato de ciproterona.